Redmile Group LLC 13D and 13G filings for Neoleukin Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-07-27 5:15 pm Sale |
2023-07-17 | 13D | Neoleukin Therapeutics, Inc. NLTX |
Redmile Group LLC | 145,611 6.600% |
-5,917 (-3.90%) |
Filing |
| 2023-02-14 4:21 pm Sale |
2022-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX |
Redmile Group LLC | 151,528 6.900% |
-64,550 (-29.87%) |
Filing |
| 2022-02-14 5:07 pm Purchase |
2021-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX |
Redmile Group LLC | 216,078 9.900% |
6,295 (+3.00%) |
Filing |
| 2021-02-16 4:10 pm Purchase |
2020-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX |
Redmile Group LLC | 209,783 9.900% |
209,783 (New Position) |
Filing |